Purchase this article with an account.
T. Higashiyama, O. Sawada, M. Kakinoki, T. Sawada, H. Kawamura, M. Ohji; Prospective Comparison of the Effects of Intravitreal Injections of Bevacizumab and Triamcinolone Acetonide for Macular Edema Due to Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5394.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the effect of an intravitreal injection of bevacizumab with that of triamcinolone acetonide (TA) for macular edema due to branch retinal vein occlusion (BRVO).
Forty eyes of 40 patients with macular edema due to BRVO were assigned randomly to either an intravitreal 1.25-mg bevacizumab injection or intravitreal 4-mg TA injection. All patients were followed for 3 month without additional treatment. The changes in the best-corrected visual acuity (BCVA) (logMAR) and the central retinal thickness (CRT) were measured at 1 week and 1 and 3 months after the injection.
Nineteen patients in the bevacizumab group and 18 patients in the TA group completed the 3-month follow-up. Before the injection, the BCVA and CFT were, respectively, 0.59 ± 0.16 and 613 ± 191 µm in the bevacizumab group, and 0.62 ± 0.26 and 638 ± 193 µm in the TA group, differences that were not significantly different. The BCVA in the bevacizumab group improved at all visits compared to baseline (p<0.05). The BCVA in the TA group did not improve at any visit compared to baseline. The difference between the two groups did not reach significance. The CRT in both groups decreased significantly (p<0.05) at all time points. The mean changes in the CRT between the bevacizumab group and the TA group were not significantly different at 1 week and 1 month after the injection; however, the change in the TA group was significantly (p<0.05) better compared to the bevacizumab group 3 months after the injection.
Intravitreal TA is effective and seems to maintain the treatment effect longer compared to intravitreal bevacizumab for macular edema due to BRVO.
Clinical Trial: :
This PDF is available to Subscribers Only